<DOC>
	<DOCNO>NCT01937728</DOCNO>
	<brief_summary>The purpose study : 1 . To test 36 week standard dose ribavirin PEGASYS® non-inferior standard dose 48 week ribavirin PEGASYS® SVR patient RVR HVL 2 . To test 72 week treatment PEGASYS® plus standard dose ribavirin superior 48 week treatment patient HCV RNA seropositivity week 12</brief_summary>
	<brief_title>Tailored Regimens PEGASYS® Ribavirin Genotype 1 Chronic Hepatitis C Patients Trial ( TARGET-1 )</brief_title>
	<detailed_description>The aim present study : 1 . To evaluate efficacy safety 36-week versus 48-week regimen PEGASYS® ( peginterferon alfa-2a , PegIFN ) plus standard-dose ribavirin ( RBV ) hepatitis C virus ( HCV ) genotype 1 infected , treatment-naïve CHC patient high viral load ( HVL , define baseline HCV RNA ≧ 400,000 IU/mL ) achieve rapid virologic response ( RVR ) ( define seronegativity HCV RNA week 4 treatment ) 2 . To evaluate efficacy safety 48-week versus 72-week regimen PegIFN plus standard-dose RBV HCV virus genotype 1 infect , treatment-naïve CHC patient PCR-seropositive HCV RNA week 12</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Male female patient *18 year age Patients never treat traditional interferon plus ribavirin peginterferon plus ribavirin Serologic evidence chronic hepatitis C infection antiHCV antibody test Detectable serum HCVRNA HCV viral genotype 1 Liver biopsy finding consistent diagnosis chronic hepatitis C infection without compensate cirrhosis ( Exception : hemophiliac biopsy medically contraindicate require biopsy . ) Compensated liver disease ( ChildPugh Grade A clinical classification ) Negative urine blood pregnancy test ( woman childbearing potential ) document within 24hour period prior first dose study drug All fertile male females receive ribavirin must use two form effective contraception treatment 6 month treatment end Women ongoing pregnancy breast feed Therapy systemic antineoplastic immunomodulatory treatment ( include supraphysiologic dos steroid radiation ) *6 month prior first dose study drug Any investigational drug *6 week prior first dose study drug Coinfection active hepatitis A , hepatitis B and/or human immunodeficiency virus ( HIV ) History evidence medical condition associate chronic liver disease HCV ( e.g. , hemochromatosis , autoimmune hepatitis , metabolic liver disease , alcoholic liver disease , toxin exposure ) Signs symptom hepatocellular carcinoma History evidence bleed esophageal varix condition consistent decompensated liver disease Neutrophil count &lt; 1500 cells/mm3 platelet count &lt; 90,000 cells/mm3 screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Genotype 1</keyword>
	<keyword>Peg interferon</keyword>
	<keyword>alfa 1a</keyword>
	<keyword>Ribavirin</keyword>
</DOC>